Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech's 2009 Revenues Rise 81 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Osmetech today reported that its full-year 2009 revenues increased 81 percent, while the firm cut its net loss by 16 percent.

The British molecular diagnostics firm announced separately that has filed with the US Securities and Exchange Commission for an initial public offering of stock in the US under the name of its newly proposed parent, GenMark Diagnostics.

Osmetech's total revenues for the year were £638,186 ($961,753) compared to £352,069 for FY 2008. The firm said that the increase was due to growth in sales of its cystic fibrosis genotyping test and a warfarin sensitivity test. It added that currency translation accounted for 27 percent of the revenue growth.

Osmetech's net loss for 2009 dropped to £13 million, or 1.25 pence, from £15.5 million, or 6.66 pence.

The company said that its R&D expenses fell 33 percent to £1.8 million from £2.7 million, due primarily to the completion of development of its eSensor XT-8 System in 2008. It did not provide SG&S expenses.

Osmetech finished 2009 with £10.2 million in cash and cash equivalents.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.